Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 44
Filter
1.
Drug Dev Ind Pharm ; 44(7): 1171-1184, 2018 Jul.
Article in English | MEDLINE | ID: mdl-29429379

ABSTRACT

INTRODUCTION: In this study, different nifedipine-loaded formulations were prepared to treat pylorospasm, a sphincter muscle disorder characterized by delayed gastric emptying process. The efficacy of formulation was evaluated in patients by subjective assessment, gamma scintigraphic approaches, and confocal microscopy. METHODS: Nifedipine-loaded different formulations such as sucrose bead, pellets, and microparticles (slugging method, ionotropic gelation, and chemical denaturation) were designed. The studies were performed on 50 subjects, of which 30 subjects were treated with optimized nifedipine loaded microcapsules while 20 subjects were given capsule becosule-Z as a control. The efficacy of formulation was assessed by comparing symptoms like dyspepsia, abdominal pain, abdominal fullness, poor appetite, nausea, vomiting, and irregular motion. The effectiveness of formulation was also assessed by gamma scintigraphic studies by determining the rate of emptying of a radioactivity labeled standard meal from patients' stomach into the duodenum. Confocal microscopy was used to assess targeting potential of developed formulation. RESULTS: Drug-loaded alginate-chitosan microcapsules were found to be satisfactory, in terms of controlled drug release, surface morphology, and bioadhesive properties and thus selected for in vivo studies. Clinical studies revealed the efficacy of formulation in abolishing various GI symptoms at high altitude. Associated symptoms such as dyspepsia, abdominal pain, poor appetite, nausea, vomiting, and irregular motion were recovered by 75, 62, 76.5, 86.7, 85.7, and 37.5%, respectively in nifedipine-treated patients. In comparison, 73.7, 40, 33.3, 40, 20, and 0% recoveries were observed in patients given control treatment only. Gamma Scintigraphic studies in lab also revealed 2.425 ± 0.245 (p < .05) times improvement in gastric emptying rate in patients with diabetic gastroparesis. Confocal analysis showed better targeting and penetration in pyloric region when formulation was administered in form of high-density microcapsules. CONCLUSIONS: Results strongly suggest that nifedipine loaded mucoadhesive formulation has a targeting potential which accelerates gastric emptying process in gastroparesis patients, and thus the formulation might prove useful as a potent prokinetic agent.


Subject(s)
Gastrointestinal Agents/chemistry , Gastrointestinal Agents/therapeutic use , Gastroparesis/drug therapy , Nifedipine/chemistry , Nifedipine/therapeutic use , Adult , Aged , Alginates/chemistry , Animals , Chemistry, Pharmaceutical/methods , Chitosan/chemistry , Delayed-Action Preparations/chemistry , Delayed-Action Preparations/therapeutic use , Double-Blind Method , Female , Gastric Emptying/drug effects , Glucuronic Acid/chemistry , Hexuronic Acids/chemistry , Humans , Male , Middle Aged , Muscular Diseases/drug therapy , Rats , Rats, Wistar , Stomach/drug effects
2.
Eur J Pharm Biopharm ; 126: 221-232, 2018 May.
Article in English | MEDLINE | ID: mdl-28629719

ABSTRACT

The purpose of this research work was to prepare nanosized formulation of alpha ketoglutarate as dry powder inhaler for cyanide poisoning. Nanosizing can be approached by solid phase and liquid phase method. The different conditions encountered in both these approaches can greatly affect the particle characteristics. In this study milling and precipitation technique were compared to study their effect on α-KG particles characteristics. Differences in choice of stabilizers were observed between the two processing techniques. Sonication processes followed by HPH produced small sized particles in which Pluronic F68 was employed as stabilizing agent. Precipitation approach produced ultrafine drug particles by utilizing combination of stabilizers (PVA+PEG 400). Amongst the two sonication processes, probe sonication process produced well stabilized small sized particles. The designed particles showed 43.13±2.36% lung deposition when compared with ultrasonication and precipitation technique that showed 31.69% and 21.67% respirable fraction. The MMAD of the designed particles was found suitable for deep alveolar deposition. Clinical studies (Phase-I trial) showed whole lung deposition of 52.51% for DPI. The P/C ratio was found to be 1.02 suggesting uniform distribution of particles in different lung compartments.


Subject(s)
Cyanides/poisoning , Ketoglutaric Acids/administration & dosage , Ketoglutaric Acids/metabolism , Lung/metabolism , Nanoparticles/administration & dosage , Nanoparticles/metabolism , Administration, Inhalation , Adult , Humans , Lung/drug effects , Male , Particle Size , Radionuclide Imaging/methods
3.
J Cancer Res Clin Oncol ; 142(10): 2073-106, 2016 Oct.
Article in English | MEDLINE | ID: mdl-27116692

ABSTRACT

PURPOSE: Most of the nanomedicines for treatment of multidrug-resistant cancer do not reach Phase III trials and many are terminated or withdrawn or are in an indeterminate state since long without any study results being presented. Extensive perusal of nanomedicine development research revealed that one of the critical aspects influencing clinical outcomes and which requires diligent scrutiny is selection process of nanodelivery system. METHODS: Research papers and articles published on development of nanodelivery systems for treatment of multidrug-resistant cancer were analyzed. Observations and conclusions noted by these researchers which might shed some light on poor clinical performance of nanocarriers were collated and summarized under observation section. Further research articles were studied to find possible solutions which may be applied to these particular problems for resolving them. The inferences of these findings were composed in Result section. RESULT: Plausible solutions for the observed obstacles were noted as examples of novel formulations that can yield the following: better in vivo imaging, precise targeting and dosing of a specific site and specific cell type in a particular cancer, modulation of tumor surroundings, intonation of systemic effects and high reproducibility. CONCLUSION: The angle of approach to the development of best nanosystem for a specific type of tumor needs to be spun around. Some of these changes can be brought about by individual scientists, some need to be established by collated efforts of scientists globally and some await advent of better technologies. Regardless of the stratagem, it can be said decisively that the schematics of development phase need rethinking.


Subject(s)
Drug Delivery Systems/methods , Nanomedicine/methods , Neoplasms/drug therapy , Clinical Trials as Topic , Drug Resistance, Neoplasm , Humans
4.
J Pharm Bioallied Sci ; 7(4): 308-13, 2015.
Article in English | MEDLINE | ID: mdl-26681890

ABSTRACT

OBJECTIVE: The present study was used to design simple, accurate and sensitive reversed phase-high-performance liquid chromatography RP-HPLC and high-performance thin-layer chromatography (HPTLC) methods for the development of quantification of khellin present in the seeds of Ammi visnaga. MATERIALS AND METHODS: RP-HPLC analysis was performed on a C18 column with methanol: Water (75: 25, v/v) as a mobile phase. The HPTLC method involved densitometric evaluation of khellin after resolving it on silica gel plate using ethyl acetate: Toluene: Formic acid (5.5:4.0:0.5, v/v/v) as a mobile phase. RESULTS: The developed HPLC and HPTLC methods were validated for precision (interday, intraday and intersystem), robustness and accuracy, limit of detection and limit of quantification. The relationship between the concentration of standard solutions and the peak response was linear in both HPLC and HPTLC methods with the concentration range of 10-80 µg/mL in HPLC and 25-1,000 ng/spot in HPTLC for khellin. The % relative standard deviation values for method precision was found to be 0.63-1.97%, 0.62-2.05% in HPLC and HPTLC for khellin respectively. Accuracy of the method was checked by recovery studies conducted at three different concentration levels and the average percentage recovery was found to be 100.53% in HPLC and 100.08% in HPTLC for khellin. CONCLUSIONS: The developed HPLC and HPTLC methods for the quantification of khellin were found simple, precise, specific, sensitive and accurate which can be used for routine analysis and quality control of A. visnaga and several formulations containing it as an ingredient.

5.
Indian J Pharm Sci ; 77(1): 14-23, 2015.
Article in English | MEDLINE | ID: mdl-25767314

ABSTRACT

The present work is aimed to develop a simple, sensitive, robust and reliable HPLC method for the estimation of irinotecan in the physiological media in order to assess the permeability profile of irinotecan, using the everted gut sac, in the presence of various P-gp modulators. Separation was achieved using, C18 column with mobile phase consisting of acetonitrile and 0.045 µM sodium dihydrogen phosphate dihydrate buffer containing ion pair agent heptane sulphonic acid sodium salt (0.0054 µM), pH 3. The flow rate was maintained at 1 ml/min and analysis was performed at 254.9 nm using PDA detector. Calibration data showed an excellent linear relationship between peak-area verses drug concentration (r(2), 0.9999). Linearity was found to be in the range of 0.060-10.0 µg/ml. Limits of detection and quantification were found to ~0.020 µg/ml and ~0.060 µg/ml, respectively. The developed method was found to be precise (RSD < 1.5%, for repeatability and <2.55% for intermediate precision, acceptable ranges of precision), accurate (The recovered content of irinotecan in the presence of various P-gp modulators varied from 96.11-101.51%, within acceptable range, 80-120%), specific and robust (% RSD < 2). Developed method has been applied successfully for the evaluation of eleven P-gp modulators from diverse chemical class.

6.
Indian J Pharm Sci ; 77(6): 723-8, 2015.
Article in English | MEDLINE | ID: mdl-26997700

ABSTRACT

A simple, rapid, reliable, robust and optimized reversed phase high performance liquid chromatographic method for simultaneous estimation of doxycycline hyclate and curcumin was successfully developed and validated as per International Conference on Harmonization guidelines. The objective was achieved in terms of well separated peaks within 10 min on a Waters Sunfire C8 column with dimensions of 250×4.6 mm, particle size 5.0 µm using mobile phase consisting of 30 volumes of potassium dihydrogen phosphate buffer (50 mM) adjusted to pH 6.5±0.1 with triethylamine and 70 volumes of methanol at flow rate of 0.85 ml/min. The column effluents were monitored at 400 nm maintained at ambient column temperature (28(o)). The developed method was found linear over the concentration range of 200-700 µg/ml for doxycycline hyclate and 8-28 µg/ml for curcumin, the detection and quantitation limit was found to be 26.063 and 78.97 µg/ml for doxycycline hyclate; 0.795 and 2.13 µg/ml for curcumin, respectively. The developed method was optimized using Minitab software version 16 to meet the current quality by design requirements. The method validation was done for linearity, range, detection and quantitation limit, accuracy, precision, specificity, system suitability testing, and robustness.

7.
Indian J Pharm Sci ; 76(5): 462-5, 2014 Sep.
Article in English | MEDLINE | ID: mdl-25425764

ABSTRACT

For the prevention of postoperative ocular infections prophylactic topical antibiotics are routinely used. Studies evaluating comparative difference between single dose versus multiple dose administration on aqueous humour concentration of moxifloxacin are lacking. This study compared the aqueous humour concentration of moxifloxacin following its topical administration in rabbit eyes with two dose regimens. Twelve albino rabbits were divided into two groups. In group-1, two drops were administered thrice (total six drops) at 2 min intervals, in both the eyes; in group-2, two drops of moxifloxacin were administered three times a day for three days and also two h before aqueous humour collection i.e. on fourth day. Mean aqueous humour concentrations were calculated and compared using Student's 't' test and P<0.05 was considered significant. Moxifloxacin concentration in aqueous humour in group-1 was 23.79 µg/ml and in group-2 was 42.08 µg/ml. Both dosing regimens produced substantially higher aqueous concentrations than the known minimum inhibitory concentration for most bacteria. Moxifloxacin concentration in aqueous humour with multiple instillations is significantly higher than single instillation (P<0.05), which is adequate to cover ciprofloxacin-resistant gram-negative bacteria. Repeated topical moxifloxacin administration achieved significantly higher aqueous humour concentrations than single administration.

8.
Drug Dev Ind Pharm ; 40(9): 1206-12, 2014 Sep.
Article in English | MEDLINE | ID: mdl-23826860

ABSTRACT

Diterpenoidal anti-cancer drug andrographolide (AD) was encapsulated into solid lipid nanoparticle (SLN) because of poor aqueous solubility and high lipophilicity. AD-SLNs were prepared by solvent injection method and characterized for droplet size, surface morphology, zeta potential, etc. In vitro drug release was carried out by dialysis-membrane method. A pharmacokinetic study was performed by UPLC/Q-TOF-MS method to determine the maximum plasma concentration (Cmax), area under the curve (AUC), etc. There was an improvement in Cmax and AUC of AD-SLNs when compared with AD, thereby enhancing the bioavailability of AD. The tmax was increased than that of AD suspension, indicating the sustained release pattern of AD-SLNs. The antitumor activity was carried out on Balb/c mice showing better results with AD-SLNs as compared to AD. Thus, the AD-loaded SLNs would be useful for delivering poorly water-soluble AD with enhanced bioavailability and improved antitumor activity.


Subject(s)
Antineoplastic Agents/chemistry , Antineoplastic Agents/pharmacology , Diterpenes/chemistry , Diterpenes/pharmacology , Lipids/chemistry , Lipids/pharmacology , Nanoparticles/chemistry , Animals , Antineoplastic Agents/pharmacokinetics , Area Under Curve , Biological Availability , Cell Line, Tumor , Chemistry, Pharmaceutical/methods , Diterpenes/pharmacokinetics , Female , Humans , Lipids/pharmacokinetics , MCF-7 Cells , Mice , Mice, Inbred BALB C , Particle Size , Solubility , Solvents/chemistry , Suspensions/chemistry , Suspensions/pharmacology , Water/chemistry
9.
Parasitol Res ; 113(2): 681-91, 2014 Feb.
Article in English | MEDLINE | ID: mdl-24366812

ABSTRACT

The present study reports on the antifilarial activity of poly (lactic-co-glycolic acid) nanoparticles encapsulated ivermectin (nano-IVM) against human lymphatic filariid Brugia malayi in rodent host Mastomys coucha. Nano-IVM was prepared and optimized by nanoprecipitation method. The selected nano-IVM (F5) showed a uniform spherical shape with 96 nm diameter and 74.12 % entrapment efficiency, and when used at a suboptimal dose of 100 µg/kg body weight, completely eliminated filarial parasites from systemic circulation on 60 days post-infection in animals inflicted with B. malayi. In contrast, the coadministration of nano-IVM (F5) along with standard filaricide diethylcarbamazine (DEC) was found to be competent enough to suppress microfilarial stage of parasites and successfully eliminated microfilaria at 45 days posttreatment. However, the free form of both the drugs alone or in combination was unable to impart such suppression and followed by recurrence of the infection. Interestingly, nano-IVM (F5) was also found to be effective against adult stage parasites causing 36.67 % worm mortality and 75.89 % in combination with DEC; however, female sterilization remain almost similar. Thus, the combination of entrapped IVM with DEC exhibited enhanced microfilaricidal and marginally better macrofilaricidal efficacy than any of the single formulation or drugs combination.


Subject(s)
Brugia malayi/drug effects , Filariasis/drug therapy , Filaricides/administration & dosage , Ivermectin/administration & dosage , Lactic Acid , Nanocapsules , Polyglycolic Acid , Animals , Diethylcarbamazine/administration & dosage , Diethylcarbamazine/pharmacokinetics , Diethylcarbamazine/pharmacology , Diethylcarbamazine/therapeutic use , Female , Filariasis/parasitology , Filaricides/pharmacokinetics , Filaricides/pharmacology , Ivermectin/pharmacokinetics , Ivermectin/pharmacology , Male , Microfilariae/drug effects , Murinae , Nanocapsules/ultrastructure , Parasite Load , Parasitic Sensitivity Tests , Particle Size , Polylactic Acid-Polyglycolic Acid Copolymer , Polyvinyl Alcohol
10.
Saudi Pharm J ; 21(3): 293-304, 2013 Jul.
Article in English | MEDLINE | ID: mdl-23960846

ABSTRACT

The present work deals with various attempts to prepare a gastroretentive formulation of lacidipine for treating gastroparesis. High density sucrose beads were modified by coating with certain polymers, but unfortunately sustained release could not be achieved. Granules were prepared by wet granulation technology using different combinations of polymers and a release of the drug was observed. The method failed to release the drug as per desired specifications. Polymeric coating followed by wet granulation was thought to be a better process to sustain the dissolution rate. The release rate can be modified by the incorporation of different polymeric coatings, but the mucoadhesive potential of granules was only 4.23% which might be due to its large size and the presence of other ingredients. Further, the lacidipine loaded microparticles were prepared by different methods such as compression, ionic gelation with TPP, ionic gelation with TPP and glutaraldehyde, spray drying and coacervation techniques. The formulations were evaluated for average particle size, surface morphology, entrapment efficiency, % yield and mucoadhesive potential. The microparticles prepared by compression method using HPMC K4M and SCMC as mucoadhesive polymers and BaSO4 as high density diluent showed poor bioadhesion (8.3%) and poor release characteristics (100% in 120 min). Ionic gelation with tripolyphosphate yielded microspheres with poor mechanical strength. In order to improve its mechanical strength, TPP ionic gelation was combined with step-wise cross-linking with glutaraldehyde. The additional solidification step to improve mechanical strength left this procedure tedious, time consuming and cytotoxic. Spray drying method gave a very low yield with 46.67% bioadhesion. The method using CaCl2 for ionotropic gelation showed the best results with regard to physical characteristics (well formed discrete, spherical surface microcapsule), particle size (88.57 ± 0.51), in vitro bioadhesion (67.33%), yield (>85%) and loading (>70%).

11.
Pharmazie ; 67(10): 834-8, 2012 Oct.
Article in English | MEDLINE | ID: mdl-23136716

ABSTRACT

A simple, rapid, precise and accurate isocratic reversed-phase high performance liquid chromatography (HPLC) method was developed and validated for the simultaneous determination of paclitaxel and ellagic acid in a combination nanoformulation. Separation was achieved using a 25 x 4.6 mm column, particle size 5 microm C18 reverse phase column (Luna), with a mobile phase consisting of methanol and 0.05% H3PO4, in gradient elution mode with a mobile phase flow rate of 1 mL/min, using UV visible detection at 230 nm. Sharp and well defined peaks were obtained at retention times of 13.75 min. and 11.6 min. for paclitaxel and ellagic acid, respectively. Regression analysis showed a good linear relationship (r2 = 0.996 +/- 0.0011) and (r2 = 0.993 +/- 0.0011) over wide ranges of 5-500 microg/ml and 1-500 microg/ml for paclitaxel and ellagic acid, respectively. LOD and LOQ of paclitaxel were 30 ng/ml and 100 ng/ml, respectively, while for ellagic acid LOD and LOQ were 300 ng/ml and 1 microg/ml, respectively. The accuracy of the method was determined by recovery studies using the standard addition method and was found to be in the range of 99.61-101.21% and 98.70-102.22% for paclitaxel and ellagic acid, respectively. The relative standard deviation (% RSD) for precision, repeatability and robustness was less than 2%. The ellagic acid content in fruits of Punica granatum and combination formulation with paclitaxel was analyzed and found to be 0.04% w/w and 0.0012%w/w, respectively. The proposed, developed and validated HPLC method for the simultaneous quantification of ellagic acid and paclitaxel can be used for the quality control and standardization of several crude drugs and different combination formulations, in which ellagic acid is present.


Subject(s)
Antineoplastic Agents, Phytogenic/analysis , Ellagic Acid/analysis , Lythraceae/chemistry , Paclitaxel/analysis , Calibration , Chemistry, Pharmaceutical , Chromatography, High Pressure Liquid , Fruit/chemistry , Indicators and Reagents , Linear Models , Plant Extracts/analysis , Reference Standards , Reproducibility of Results , Spectrophotometry, Ultraviolet
12.
Vaccine ; 30(43): 6198-209, 2012 Sep 21.
Article in English | MEDLINE | ID: mdl-22871353

ABSTRACT

Tuberculosis kills two million people each year. As the current vaccine BCG fails to prevent adult cases of TB, an improved vaccine and/or vaccination strategy is urgently needed to combat TB. Previously we reported the higher protective efficacy of Mycobacterium indicus pranii (MIP), formerly known as Mycobacterium w (M.w) as compared to BCG in murine model of TB. In this study we further evaluated the protective efficacy of MIP in guinea pig model of TB. Modulation of post infection immune response was analyzed in the lungs of MIP immunized and control groups. We found reduced bacterial loads, improved pathology and organized granulomatous response at different post infection time points in the MIP-immunized group as compared to the BCG-immunized group. Combined results suggest that MIP-immunization results in heightened protective Th1 response as compared to BCG group, early after infection with M.tb and a balanced Th1 versus immunosuppressive response at late chronic stage of infection. The study demonstrates the higher antigen presenting cells function both inside the granuloma as well as in the single cell suspension of the lung in the MIP-immunized group. We further demonstrate that live MIP is safe to use in vivo as we observed quick clearance of MIP from the body and no untoward reaction was found. Aerosol route of immunization provided higher protection. Further this study provides evidence that MIP-immunization gives significantly better long term protection as compared to BCG against TB.


Subject(s)
Lung/immunology , Mycobacterium/immunology , Tuberculosis Vaccines/immunology , Tuberculosis, Pulmonary/prevention & control , Animals , Apoptosis , Bacterial Load , Cell Line , Cytokines/immunology , Female , Granuloma/immunology , Granuloma/microbiology , Granuloma/pathology , Guinea Pigs , Lung/pathology , Macrophages/immunology , Mice , Mice, Inbred C57BL , Neutrophils/immunology , Th1 Cells/immunology , Tuberculosis, Pulmonary/pathology
13.
J Pharm Bioallied Sci ; 4(2): 134-9, 2012 Apr.
Article in English | MEDLINE | ID: mdl-22557924

ABSTRACT

OBJECTIVE: A simple, sensitive, and specific thin layer chromatography (TLC) densitometry method has been developed for the simultaneous quantification of strychnine and brucine in the seeds of Strychnos nux-vomica. MATERIALS AND METHODS: The method involved simultaneous estimation of strychnine and brucine after resolving it by high performance TLC (HPTLC) on silica gel plate with chloroform-methanol-formic acid (8.5:1.5:0.4 v/v/v) as the mobile phase. RESULTS: The method was validated as per the ICH guidelines for precision (interday, intraday, intersystem), robustness, accuracy, limit of detection, and limit of quantitation. The relationship between the concentration of standard solutions and the peak response was linear within the concentration range of 50-1000 ng/spot for strychnine and 100-1000 ng/spot for brucine. The method precision was found to be 0.58-2.47 (% relative standard deviation [RSD]) and 0.36-2.22 (% RSD) for strychnine and brucine, respectively. Accuracy of the method was checked by recovery studies conducted at three different concentration levels and the average percentage recovery was found to be 100.75% for strychnine and 100.52% for brucine, respectively. CONCLUSIONS: The HPTLC method for the simultaneous quantification of strychnine and brucine was found to be simple, precise, specific, sensitive, and accurate and can be used for routine analysis and quality control of raw material of S. nux-vomica and several unani and ayurvedic formulations containing this as an ingredient.

14.
Pharmazie ; 66(12): 956-60, 2011 Dec.
Article in English | MEDLINE | ID: mdl-22312702

ABSTRACT

The present paper describes the advantage of PEG-ylation of L-asparaginase before encapsulation over its incorporation in the native form. During encapsulation a considerable amount of native protein undergoes denaturation and forms insoluble aggregates. In an effort to overcome this problem, L-asparaginase was PEG-ylated before subjecting it to the harsh conditions as encountered during double emulsion solvent evaporation technique. L-asparaginase was conjugated with succinimidyl succinate derivative of polyethylene glycol (SS-PEG, MW 5000) followed by characterization of the formed conjugate using size exclusion-HPLC and SDS PAGE. The PEG-ylated L-asparaginase consisted of different isomers from mono to multi PEG-ylated depending upon the number of Lysine residues (14 in case of L-asparaginase) with about 5% as native protein. The specific activity as retained after PEG-ylation was 62.84 +/- 8.2% and further about 82.7% of activity was recovered from the particles. Imitated studies with the native protein confirmed the enhanced stability of the conjugated protein when exposed to the organic solvent and sonication and showed comparatively less encapsulation efficiency due to increased hydrophilicity. Release profiles for native as well as conjugated proteins consisted of sustained release of about 66.66% and 44.45% in 28 days, respectively. The decrease in the release can be attributed to the increase in the molecular weight of the conjugated protein. The study finally proved that PEG-ylation protected the enzyme and prevented it from denaturation during encapsulation.


Subject(s)
Asparaginase/administration & dosage , Asparaginase/chemistry , Lactic Acid , Polyethylene Glycols/chemistry , Polyglycolic Acid , Chromatography, Gel , Chromatography, High Pressure Liquid , Computer Simulation , Drug Compounding , Drug Delivery Systems , Electrophoresis, Polyacrylamide Gel , Emulsions , Lysine/chemistry , Microscopy, Electron, Scanning , Molecular Weight , Nanoparticles , Polylactic Acid-Polyglycolic Acid Copolymer , Rheology , Solvents , Ultrasonics
15.
Indian J Pharm Sci ; 72(6): 675-88, 2010 Nov.
Article in English | MEDLINE | ID: mdl-21969738

ABSTRACT

Nucleic acid-based therapeutics have gained a lot of interest for the treatment of diverse ophthalmic pathologies. The first to enter in clinic has been an oligonucleotide, Vitravene(®) for the treatment of cytomegalovirus infection. More recently, research on aptamers for the treatment of age related macular degeneration has led to the development of Macugen(®). Despite intense potential, effective ocular delivery of nucleic acids is a major challenge since therapeutic targets for nucleic acid-based drugs are mainly located in the posterior eye segment, requiring repeated invasive administration. Of late, nanotechnology-based nano-vectors have been developed in order to overcome the drawbacks of viral and other non-viral vectors. The diversity of nano-vectors allows for ease of use, flexibility in application, low-cost of production, higher transfection efficiency and enhanced genomic safety. Using nano-vector strategies, nucleic acids can be delivered either encapsulated or complexed with cationic lipids, polymers or peptides forming sustained release systems, which can be tailored according to the ocular tissue being targeted. The present review focuses on developments and advances in various nano-vectors for the ocular delivery of nucleic acid-based therapeutics, the barriers that such delivery systems face and methods to overcome them.

16.
Pharmazie ; 64(11): 735-40, 2009 Nov.
Article in English | MEDLINE | ID: mdl-20099518

ABSTRACT

The present study explored the transdermal permeation enhancing mechanism of non-ionic surfactant vesicles (proniosomes) of frusemide across rat skin. Fourier Transform Infrared Spectroscopy (FT-IR), Differential Scanning Calorimetry (DSC), activation energy and histological examination were carried out to study the mode of action of the optimized proniosome formulations PGS [Span 40:soyalecithin:cholesterol (4.5:4.5:1)] and PGD [Span 40:dicetylphosphate:cholesterol (4.5:4.5:1)]. The IR spectra showed a prominent decrease in peak areas and heights of CH2 stretchings but did not show shift of these peaks and shift in amide bands. DSC studies also confirmed the IR findings. It was concluded that the proniosomes disrupted the lipid bilayer by extracting the lipids thereby creating pathways for drug penetration. The significant decrease in activation energy for frusemide permeation across rat skin indicated the SC lipid bilayers were significantly disrupted (p<0.05). Histological investigations were carried out. Disruption and extraction of lipid bilayers as distinct voids and empty spaces were visible in the epidermal region. Overall, our findings suggested that proniosomal formulations offer a promising means for non-invasive delivery of frusemide, especially due to their ability to modulate drug transfer and serve as non-toxic permeation enhancers.


Subject(s)
Diuretics/pharmacokinetics , Furosemide/pharmacokinetics , Skin Absorption/physiology , Animals , Calorimetry, Differential Scanning , Diuretics/administration & dosage , Furosemide/administration & dosage , In Vitro Techniques , Lipid Bilayers , Nanospheres , Rats , Spectroscopy, Fourier Transform Infrared , Surface-Active Agents/chemistry
17.
J Mater Sci Mater Med ; 20 Suppl 1: S71-6, 2009 Dec.
Article in English | MEDLINE | ID: mdl-18543087

ABSTRACT

The present study relates to enhancing the dosing efficiency of pharmaceutical dry powder formulations administered by pulmonary inhalation. In particular, the study relates to the provision of dry powder inhalers (DPI) by forming nanosized particles of salbutamol sulfate (SBM) in order to augment the drug penetrability and deposition in the lungs. SBM, an antiasthmatic was selected to be developed into a nanosized formulation by different techniques like solvation, high-pressure homogenization, and spray drying, which were then compared on the basis of particle shape, particle size, and particle size distribution. In case of solvation method the nanosuspension was prepared by dispersing SBM into a nonsolvent and adding Tween-80 as a surfactant to prevent the agglomeration, the particles obtained therein were in the range of 2-10 mu. The second attempt was made by passing the suspension of SBM through high-pressure homogenizer at 10,000-15,000 psi. A treatment of six cycles of homogenization in presence of a Tween-80 as surfactant was found to give a nanosuspension within a size range 50-100 nm. The only drawback seemed with this technique was the low-product yield and high-processing time (3-4 h). In order to overcome this drawback spray-drying technique was further explored; the solution of SBM containing Tween-80 was stirred on magnetic stirrer at 1,200 rpm and finally dried by using spray dryer at an inlet and outlet temperature of 75 degrees C and 56 degrees C, respectively. The feed rate for spray dryer was kept to be 91 ml/h. The sample was collected and analyzed for particle size distribution which was found to be in the range of 50-100 nm. Keeping in view the positive outcomes in terms of higher yield and lower processing time, the spray-drying technique was taken to give the optimized formulation. Nanosized particles, thus obtained were evaluated for particle size, surface topology and particles size distribution, by Transmission Electron Microscopy (TEM), Scanning Electron Microscopy (SEM), and Quasi-elastic light scattering (QELS) technique, respectively. The nanosized particles were subjected to investigate changes on the physical stability of the powder, for this different analytical method was used as: Fourier transform infrared spectroscopy (FT-IR), Differential Scanning Calorimetry (DSC) and X-ray diffraction (XRD) analysis and thus the result indicates that there was no physical disparity when compared with the commercial SBM sample.


Subject(s)
Albuterol/administration & dosage , Chemistry, Pharmaceutical/methods , Drug Carriers/chemical synthesis , Nanoparticles/chemistry , Bronchodilator Agents/administration & dosage , Calorimetry, Differential Scanning , Drug Carriers/analysis , Drug Carriers/chemistry , Microscopy, Electron, Scanning , Microscopy, Electron, Transmission , Nanoparticles/analysis , Particle Size , Spectroscopy, Fourier Transform Infrared , Surface Properties , X-Ray Diffraction
18.
Pharm Dev Technol ; 14(1): 96-105, 2009.
Article in English | MEDLINE | ID: mdl-18821127

ABSTRACT

In the present study, a Box-Behnken experimental design was employed to statistically optimize the formulation parameters of chitosan phthalate and chitosan succinate microspheres preparation. These microspheres can be useful for oral insulin delivery system. The effects of three parameters namely polymer concentration, stirring speed and cross linking agent were studied. The fitted mathematical model allowed us to plot response surfaces curves and to determine optimal preparation conditions. Results clearly indicated that the crosslinking agent was the main factor influencing the insulin loading and releasing. The in vitro results indicated that chitosan succinate microspheres need high amount of crosslinking agent to control initial burst release compared to chitosan phthalate microspheres. The reason may be attributed that chitosan succinate is more hydrophilic than chitosan phthalate. The relative pharmacological efficacy for chitosan phthalate and chitosan succinate microspheres (18.66 +/- 3.84%, 16.24 +/- 4%) was almost three-fold higher than the efficacy of the oral insulin administration (4.68 +/- 1.52%). These findings suggest that these microspheres are promising carrier for oral insulin delivery system.


Subject(s)
Chitosan/administration & dosage , Hypoglycemic Agents/administration & dosage , Insulin/administration & dosage , Microspheres , Administration, Oral , Animals , Chemistry, Pharmaceutical , Chitosan/chemical synthesis , Hypoglycemic Agents/blood , Insulin/blood , Insulin/chemistry , Kinetics , Models, Statistical , Particle Size , Rats , Research Design , Technology, Pharmaceutical
19.
J Microencapsul ; 26(5): 385-93, 2009 Aug.
Article in English | MEDLINE | ID: mdl-18720200

ABSTRACT

The purpose of this research work was to formulate and systematically evaluate in vitro performance of mucoadhesive microspheres of lacidipine for treatment of pylorospasm. Lacidipine microspheres containing chitosan were prepared by chemical denaturation using glutaraldehyde as a cross-linking agent. The microspheres were evaluated for physical characteristics such as particle size, particle shape and surface morphology by scanning electron microscopy, drug entrapment efficiency and in vitro mucoadhesion. Results of preliminary trials indicated that the polymer concentration, cross-linking agent and stirring speed had a noticeable effect on size and surface morphology. A central composite design was employed to study the effect of independent variables, polymer concentration (X(1)), volume of glutaraldehyde (X(2)), stirring speed (X(3)) and cross-linking time (X(4)) on dependent variables, drug entrapment efficiency and percentage mucoadhesion. The entrapment efficiency varied from 14-40.82% depending upon the polymer concentration, volume of cross-linker and stirring speed. All batches of microspheres exhibited good mucoadhesive property (73-83%) in the in vitro wash-off test. It was observed that polymer concentration and glutaraldehyde volume had a more significant effect on the dependent variables. Maximum entrapment (36.53%) and mucoadhesion (81.33%) was predicted at 3.5% chitosan, 3 ml glutaraldehyde, 3000 rpm stirring speed and 75 min cross-linking time under optimized process condition. The selected formulation showed controlled release for more than 6 h. The release followed Higuchi kinetics via a Fickian diffusion.


Subject(s)
Dihydropyridines/chemistry , Dihydropyridines/pharmacology , Drug Compounding/methods , Gastrointestinal Transit , Microspheres , Pylorus/drug effects , Pylorus/physiopathology , Adhesiveness , Animals , Cross-Linking Reagents/chemistry , Dihydropyridines/administration & dosage , Dihydropyridines/pharmacokinetics , Glutaral/chemistry , In Vitro Techniques , Intestinal Mucosa/drug effects , Intestinal Mucosa/metabolism , Particle Size , Rats , Time Factors
20.
CNS Neurol Disord Drug Targets ; 7(4): 343-7, 2008 Oct.
Article in English | MEDLINE | ID: mdl-18991662

ABSTRACT

Advances in the understanding of mechanisms underlying the pathophysiology of epilepsy have led to the identification of sodium hydrogen exchanger (NHE) as one of the possible targets for future antiepileptic drugs (AEDs). There are indicators from several experimental studies that NHE inhibitors could be of significant value as potential anticonvulsants. Various in-vitro reports (brain slices) have suggested anticonvulsant potential of these agents. Recently we provided the in-vivo data on anticonvulsant efficacy of amiloride (an NHE inhibitor) in different animal models of seizure and epilepsy. In addition to blocking NHE, these agents are known to affect other traditional targets like voltage-gated Na(+) channels, Ca(2+) channels, glutamate concentration, etc. Thus NHE inhibitors may represent a novel class of AEDs and surely deserve more scientific attention. In this review, we focus on the role of NHE in epilepsy and provide the experimental evidence available so far on the effect of NHE inhibitors in various animal models.


Subject(s)
Anticonvulsants/pharmacology , Brain/drug effects , Enzyme Inhibitors/pharmacology , Epilepsy/drug therapy , Sodium-Hydrogen Exchangers/antagonists & inhibitors , Amiloride/chemistry , Amiloride/pharmacology , Amiloride/therapeutic use , Animals , Anticonvulsants/chemistry , Anticonvulsants/therapeutic use , Brain/metabolism , Brain/physiopathology , Disease Models, Animal , Enzyme Inhibitors/chemistry , Enzyme Inhibitors/therapeutic use , Epilepsy/metabolism , Epilepsy/physiopathology , Humans , Sodium Channel Blockers/chemistry , Sodium Channel Blockers/pharmacology , Sodium Channel Blockers/therapeutic use , Sodium Channels/drug effects , Sodium Channels/metabolism , Sodium-Hydrogen Exchangers/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...